Zobrazeno 51 - 60
of 341
pro vyhledávání: '"Mehmet Asim Bilen"'
Publikováno v:
Journal of Clinical Pathology. 76:256-260
AimsA subset of patients with urothelial carcinoma (UCa) and lamina propria (LP) invasion in bladder biopsies/transurethral resections (TURs) are at significant risk for recurrence and have increased rates of progression to UCa with muscularis propri
Autor:
Syed A. Hussain, Catherine Curran, Giuseppe Di Lorenzo, Ruby Gupta, Pasquale Verolino, Moshe Chaim Ornstein, Petros Grivas, Archana Agarwal, Mehmet Asim Bilen, Jorge A. Garcia, Guru Sonpavde, Alexandra Drakaki, Pedro C. Barata, Gregory R. Pond, Jae-Lyun Lee, Ravindran Kanesvaran
Publikováno v:
Clinical Genitourinary Cancer. 19:425-433
PD1/L1 inhibitors are approved by FDA as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the ou
Autor:
Kenneth Ogan, Greta Russler, Jamie M. Goldman, Bassel Nazha, Benjamin Magod, Bradley C. Carthon, Deepak Ravindranathan, Shreyas S. Joshi, Haydn T. Kissick, Yuan Liu, T. Anders Olsen, Wayne Harris, Julie M. Shabto, Omer Kucuk, Jacqueline T. Brown, Subir Goyal, Sarah Caulfield, Lauren Yantorni, Mehmet Asim Bilen, Viraj A. Master, Sean Evans, Dylan J. Martini
Publikováno v:
Oncologist
Background Several immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced urothelial carcinoma (UC). There are limited biomarkers for ICI-treated patients with UC. We investigated the association between body composition and c
Autor:
Christopher J. Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne-Sophie Carret, Jonathan E. Rosenberg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(1)
PURPOSE Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible.
Autor:
Bassel F. El-Rayes, Kathryn E. Weaver, Gelareh Sadigh, Mehmet Asim Bilen, Jane L. Meisel, David Cella, Ruth C. Carlos, David H. Lawson, Deema Elchoufi, Jeffrey M. Switchenko
Publikováno v:
Support Care Cancer
BACKGROUND: Financial toxicity is commonly reported by cancer patients, but few studies have assessed caregiver perceptions. We aimed to validate the modified Comprehensive Score for Financial Toxicity (COST) in cancer caregivers, identify factors as
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Autor:
Limeng Wan, Bradley C. Carthon, Lauren Yantorni, Omer Kucuk, Katherine Emilie Rhoades Smith, Sarah Caulfield, Jacqueline T. Brown, Greta Russler, Bassel Nazha, Mehmet Asim Bilen, Melvin R. Moore, Yuan Liu, Jennifer Ann LaFollette
Publikováno v:
Oncologist
Background Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial
Autor:
Mehmet Asim Bilen, Eduard Schreibmann, Viraj A. Master, Olayinka A. Abiodun-Ojo, Ashesh B. Jani, Vishal R. Dhere, Akinyemi A. Akintayo, Raghuveer Halkar, Bruce Hershatter, Bradley C. Carthon, Pretesh Patel, Peter J. Rossi, Omer Kucuk, Mark M. Goodman, Shreyas S. Joshi, Joseph W. Shelton, David M. Schuster, Karen M. Xu, Subir Goyal
Publikováno v:
The Lancet. 397:1895-1904
Summary Background Molecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan
Autor:
Alexandra Medline, Eric Midenberg, Dattatraya Patil, Sean Evans, Fatima Kamal, Kenneth Ogan, Sarah Psutka, Mehmet Asim Bilen, Viraj Master
Publikováno v:
Journal of Urology. 207
Autor:
Qurat Ul Ain Riaz Sipra, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, Rabbia Siddiqi, Mahnoor Islam, Noureen Asghar, Waleed Ikram, Wenxin (Vincent) Xu, Parminder Singh, Thai Huu Ho, Mehmet Asim Bilen, Yousef Zakharia, Alan Haruo Bryce
Publikováno v:
Journal of Clinical Oncology. 41:694-694
694 Background: The treatment landscape of localized renal cell carcinoma (RCC) is rapidly evolving. Recent trials have demonstrated contrasting efficacy with adjuvant immunotherapy. Therefore, we sought to assess the mixed treatment comparisons amon